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Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder exhibiting Mendelian inheritance
in some families. Next-generation sequencing approaches, including whole exome
sequencing (WES), have revolutionized the field of Mendelian disorders and have identified
a number of PD genes. We recruited a South African family with autosomal dominant PD
and used WES to identify a possible pathogenic mutation. After filtration and prioritization,
we found five potential causative variants in CFAP65, RTF1, NRXN2, TEP1 and CCNF. The
variant in NRXN2 was selected for further analysis based on consistent prediction of delete-
riousness across computational tools, not being present in unaffected family members, eth-
nic-matched controls or public databases, and its expression in the substantia nigra. A
protein model for NRNX2 was created which provided a three-dimensional (3D) structure
that satisfied qualitative mean and global model quality assessment scores. Trajectory anal-
ysis showed destabilizing effects of the variant on protein structure, indicated by high flexibil-
ity of the LNS-6 domain adopting an extended conformation. We also found that the known
substrate N-acetyl-D-glucosamine (NAG) contributed to restoration of the structural stability
of mutant NRXN2. If NRXN2 is indeed found to be the causal gene, this could reveal a new
mechanism for the pathobiology of PD.
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Introduction
Parkinson’s disease (PD), the most common neurodegenerative movement disorder, is charac-
terized by loss of dopaminergic neurons in the substantia nigra. PD affects motor, autonomic
and cognitive functioning, as well as overall mood and behavior [1]. Research on PD has firmly
established the role of genetic factors in its etiology. To date, several PD-associated genes have
been identified through linkage analysis including LRRK2, SNCA, DJ-1, PRKN, PINK1 and
SYNJ1 [2, 3]. More recently, next-generation sequencing (NGS) has contributed to the discov-
ery of novel genes including VPS35 [4, 5], CHCHD2 [6], VPS13C [7], TMEM230 [8] and
LRP10 [9]. These NGS technologies, namely whole exome sequencing (WES) and whole
genome sequencing (WGS), provide the entire exome or genome of an individual at an afford-
able cost [10]. WES generates 20,000 to 30,000 variants, per individual [11], far less compared
to WGS. However, it still requires filtration and prioritization analysis of variants into a work-
able list of candidates because it is not feasible to determine the effect of all variants, with func-
tional experiments.
Currently, there is no standard filtration protocol, and it is a lengthy and complicated task
that requires the use of several bioinformatic platforms [12]. These computational prediction
tools allow prioritization of potentially deleterious variants over other variants. Sequence-
based tools use computational algorithms based on amino acid physicochemical properties,
protein structure and cross-species conservation. These include SIFT [13], PolyPhen-2 [14],
MutationTaster [15], MAPP [16] and Panther [17]. Studies have compared multiple tools con-
cluding that the algorithms were informative and valuable in determining the impact of the
variant, although they had high rates of both false-positive and false-negative predictions [18,
19]. To address this shortfall, new meta-tools were developed such as CADD (Combined
Annotation Dependent Depletion) [20, 21]. CADD achieves better performance by combining
the predictive scores of multiple prediction tools into one unified score of potential deleteri-
ousness, and for all 8.6 billion possible human mutations, it compares variants that survived
natural selection with simulated mutations.
Assessing the frequency of genetic variants in population databases such as the Genome
Aggregation Database (gnomAD) [22], the 1000 Genomes Project [23] and dbSNP [24] can
also be used to prioritize variants. A minor allele frequency (MAF) threshold of� 1% is typi-
cally used to select potential pathogenic mutations by filtering out polymorphisms, based on
the premise that risk alleles occur at low frequencies due to negative selection against deleteri-
ous mutations [25]. Furthermore, co-segregation analysis of the variant within families is
invaluable for interpreting the variant’s significance. However, phenocopies (present at rela-
tively high levels in PD [26]) as well as non-manifesting mutation carriers need to be taken
into account in family studies.
In the present study, a multiplex South African family with PD was recruited for genetic
analysis. WES variants were filtered and prioritized using various computational tools, and
additionally structural methods (DUET webserver) and molecular dynamic simulation analy-
sis were performed. Using this approach, we excluded all known PD-associated mutations and
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performed in accordance with the relevant guidelines and regulations. Written informed con-
sent was obtained from all study participants.
Study participants
Initially, we selected 11 multiplex South African families from our PD study collection for
WES. These families were selected on the basis of having DNA available of at least two affected
second degree relatives, PD had been diagnosed by a neurologist, and at least one individual
had young-onset PD. WES was performed on a total of 24 affected individuals from these fam-
ilies. One of these families self-identified as Afrikaner and is the subject of the present study.
The Afrikaner is a group that is unique to South Africa, and whose ancestry can be traced to
people of predominantly Dutch but also German and French ancestry [27]. The family (ZA
253) comprises five PD affected individuals who were examined by a movement disorder spe-
cialist and diagnosed according to the UK Parkinson’s Disease Society Brain Bank Research
criteria [28]. A total of 218 unrelated ethnic-matched individuals were recruited as controls
from the Western Province Blood Transfusion Service in Cape Town. These individuals were
not clinically assessed for PD. Peripheral blood samples were collected from the study partici-
pants and genomic DNA was extracted according to the procedure for the phenol-chloroform
DNA extraction, as previously described [29].
Whole exome sequencing
WES was performed on three affected individuals using an Illumina HiSeq 2000, enrichment
for exonic regions was performed according to the Agilent SureSelect Custom Enrichment Kit
protocol. Burrows-Wheeler Aligner (BWA-MEM) [30] was used to align sequence reads or
assembly contigs against a large reference, duplicate removal, SNP calling and indel detection.
ANNOVAR software [31] was used to annotate the variants using GRCh37/human genome 19
as the reference genome. The Genome Analysis Toolkit (GATK) was used for variant calling
and described variants as either exonic, intronic, in the UTR or splice-site region by compari-
son with a reference sequence [31]. To provide a summary of the coverage of mapped reads on
a reference sequence at a single base pair resolution, SAMtools mpileup and the Minimum var-
iant QUAL score of 30 was used.
Validation using Sanger sequencing
Oligonucleotide primers were designed using sequence data obtained from the Ensembl
Genome Browser database (http://www.ensembl.org). In silico verification of primers was con-
ducted on Primer3 software version 4.0.0 (http://primer3.ut.ee) [32], as well as on Basic Local
Alignment Search Tool (BLAST) (http://www.ncbi.nlm.nih.gov/BLAST). Forward and reverse
PCR primers sequences, annealing temperatures and the sizes of the PCR products are avail-
able upon request.
Polymerase chain reaction (PCR)
To amplify the fragments of interest for Sanger sequencing, 25μl PCR reactions containing
template genomic DNA, 20 μmoles of each of the forward and reverse primers, 2.5 μM dNTPs
(Promega, Madison, Wisconsin, USA), 1.5 nm MgCl2, 1X Green GoTaq1 Reaction Buffer
(Promega, Madison, Wisconsin, USA) and 0.01U GoTaq1 G2 Flexi DNA Polymerase (Pro-
mega, Madison, Wisconsin, USA) was used. Amplification was performed in an ABI 2720
Thermal Cycler (Applied Biosystems Inc., Foster City, California, USA). To visualize the PCR
amplicons and to investigate if non-specific primer binding or contamination was present,
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agarose gel electrophoresis was used. PCR amplicons were visualized using a SynGene UV gel
documentation system (Synoptics Ltd., Cambridge, UK) with GeneTools software version
3.0.6 (Synoptics Ltd., Cambridge, UK).
Screening of controls
HRM analysis detects the shift in fluorescence as a double-stranded PCR product dissociates
to single-stranded DNA with increasing temperature. For this analysis, PCR was performed
with the inclusion of 1% SYTO9 fluorescent dye (Invitrogen, USA). The melting temperature
conditions ranged from 75˚C to 95˚C rising by 0.1˚C increments on a Rotor-Gene 6000 ana-
lyzer (Corbett Life Science, Australia). The resulting thermal denaturation profile is unique to
that specific PCR product, because DNA strand melting depends on sequence length, bases
and GC content (HRM Assay Design and Analysis Booklet; http://www.corbettlifescience.
com/shared/Rotor-Gene%206000/hrm_corprotocol.pdf). Samples with known variants were
included as positive controls, for comparison. A negative control was included in each run to
monitor contamination.
In-silico functional prediction tools
To investigate the variants identified, computational analysis was performed. Public mutation
databases were searched to determine the frequency of the variants, these included EXAC
Database (http://exac.broadinstitute.org/), gnomAD (https://gnomad.broadinstitute.org/), the
1000 Genomes Project (http://browser.1000genomes.org/index.html) and dbSNP (https://
www.ncbi.nlm.nih.gov/snp). Functional predictions were determined from sequence homol-
ogy–based programs namely Sorting Intolerant From Tolerant (SIFT; http://sift.jcvi.org/),
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), MutationTaster (http://www.
mutationtaster.org/) and Combined Annotation Dependent Depletion (CADD; http://cadd.
gs.washington.edu/). To determine evolutionary constraint acting on genomic sites GERP+
+ was used (http://mendel.stanford.edu/SidowLab/downloads/gerp/).
SIFT and PolyPhen-2 both report results in terms of pathogenic scores accompanied by the
prediction (Benign, Tolerated or Deleterious). MutationTaster scores the amino acid change
then reports one of two predictions based on its disease-causing threshold (Disease causing or
Neutral). CADD integrates 63 predictive features in total which includes the scores of SIFT,
GERP++, PolyPhen-2 as well as CpG distance (a short stretch of DNA in which the frequency
of the CG sequence is higher than other regions), and total GC content. It reports phred-like
scores (“scaled C-scores”) ranging from zero to 50, the variant that is predicted to be among
the 10% most deleterious substitutions that can occur in the human genome at that specific
base position, is assigned a score of 10 or greater. While variants in the 1% most deleterious
substitutions are assigned values of 20 or greater and those within 0.1% of the highest possible
substitutions at that specific locus are assigned values of 30 or greater. Thus, the higher the
CADD score the more likely it is that the variant is highly pathogenic. GERP++ uses maximum
likelihood evolutionary rate estimation for position-specific scoring, the score ranges from
-12.3 to 6.17. The closer the score is to 6.17, a value that represents the most conserved a region
can be, the greater the level of evolutionary constraint inferred to be acting on that site.
Pathway and expression analysis
To prioritize the variants, pathway analysis was performed using KEGG Pathways Analysis
(http://www.genome.jp/kegg/pathway.html) and Pathway Analysis (http://www.pantherdb.
org/pathway/).The publicly available expression databases accessed were the Allen Brain Atlas
(www.brain-map.org/) and Human Protein Atlas (https://www.proteinatlas.org/). Both
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database record human mRNA expression data but Allen brain Atlas gives only brain regional
whole-transcriptome gene expression data.
NRXN2 protein structure modelling
The three dimensional (3D) structure for human NRXN2 has not yet been resolved experi-
mentally and was predicted using the online Swissmodel Webserver [33]. Prior to modelling,
Swissmodel constructs an alignment between the target amino acid sequence of NRXN2 and
potential homologous templates by performing a position specific iterative (PSI-BLAST)
against the non-redundant protein databank (PDB) sequences [34]. Once a suitable template
was identified then the actual modelling step was invoked by submitting the alignment to the
Swissmodel webserver. Subsequent, to the modelling of NRXN2 the quality of the protein
model was assessed using Swissmodel inbuilt assessment methods Global Model Quality Esti-
mation (GMQE) and QMEAN6 composite score as well as performing a structural alignment
of atoms between the NRXN2 protein structure and the homologous template using the Pymol
align command to calculate the RMSD [35]. Usually models with a lower RMSD value suggest
very little deviation between the backbone atoms of the protein model and the homologous
template.
Molecular dynamic simulation
We prepared in total four simulation systems for NRXN2, each consisting of the wild type
(WT) NRXN2 with and without sugar moeity N-acetyl-D-glucosamine (NAG) and mutant
(MUT) structures NRNX2 with and without NAG, for simulation studies. The sugar moiety
NAG was extracted from the homologous template PDBID: 3R05 (NEUREXIN-1-ALPHA;
BOS TAURUS) by superimposition using PyMol. The NAG was included because it is impor-
tant for glycosylation of membrane proteins whereby glycans are attached to proteins neces-
sary for protein-protein interactions. All the simulations were carried out using the
GROMACS-5.1 package [36] along with the CHARMM36 all-atom force field [37]. The accu-
rate topologies for NAG was generated using SwissParam tool [38]. All four systems were sol-
vated with TIP3 water molecules in a cubic box of at least 18 Å of water between the protein
and edges of the box. To neutralize the negative charge of the WT and MUT systems without
NAG, WT and variant with NAG systems, 14, 15, 14 and 15 sodium ions were added to each
system, respectively.
Each system underwent 50,000 steps of steepest descents energy minimization to remove
close van der Waals force contacts. Subsequently, all systems were subjected to a two-step
equilibration phase namely; NVT (constant number of particles, Volume and Temperature)
for 500 ps to stabilize the temperature of the system and a short position restraint NPT (con-
stant number of particles, Pressure and Temperature) for 500 ps to stabilize the pressure of the
system by relaxing the system and keeping the protein restrained. For the NVT simulation the
system was gradually heated by switching on the water bath and the V-rescale temperature-
coupling method [39] was used, with constant coupling of 0.1 ps at 300 K under a random
sampling seed. While for NPT the Parrinello-Rahman pressure coupling [40] was turned on
with constant coupling of 0.1 ps at 300 K under conditions of position restraints (all-bonds).
For both NVT and NPT electrostatic forces were calculated using Particle Mesh Ewald method
[41]. All systems were subjected to a full 100 ns simulation and these were repeated twice for
100 ns to validate reproducibility of results. The analysis of the trajectory files was done using
GROMACS utilities. The root mean square deviation (RMSD) for backbone atoms was calcu-
lated using gmx rmsd, RMSF average per-residue analysis using gmx rmsf. The change in the
solvent accessibility surface area (SASA) for protein atoms was calculated using gmx sasa and
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the radius of gyration for the backbone atoms was calculated using gmx gyrate to determine if
the system reached stability and compactness over the 100 ns simulation. VMD [42] was used
to visually inspect changes in secondary structural elements and motion of domains along the
trajectory.
Principal component analysis
Principal component analysis (PCA) is a statistical technique that reduces the complexity of a
data set and was used here to extract biologically relevant movements of protein domains from
irrelevant localized motions of atoms. For PCA analysis the translational and rotational move-
ments was removed from the system using g_covar from GROMACS to construct a covariance
matrix. Next, the eigenvectors and eigenvalues were calculated by diagonalizing the matrix.
The eigenvectors that correspond to the largest eigenvalues are called “principal components”,
as they represent the largest-amplitude collective motions. We filtered the original trajectory
and project out the part along the most important eigenvectors namely: vector 1 and 2 using
g_anaeig from GROMACS utilities. Furthermore, we visualized the sampled conformations in
the subspace along the first two eigenvectors using g_anaeig in a two-dimensional projection.
The two-dimensional projection of the first two principal components was plotted using Gnu-
plot version 4.4 [43]. Afterwards, we calculated the free energy surface (FES) using the pro-
gram g_sham and plotted it using xpm2mat.py script and Gnuplot in a 3n matrix along the
two order parameters, Rg and RMSD. The FES represents all the possible different conforma-
tions a protein can adopt during a simulation and are typically reported as Gibbs free energy.
The molecules free energy was calculated with the formula ΔG(r) = -kBT in P(x,y)/Pmin,
where P is the probability distribution of the two variables Rg and RMSD, Pmin is the maxi-
mum probability density function, kB is the Boltzmann constant and T is the temperature of
the simulation. Conformations sampled during the simulation are projected on a two dimen-
sional plane to visualize the reduced free energy surface. The clustering of points in a specific
cell represents a possible metastable conformation. All simulations were carried out using the
GROMCS-5.1 package [36] along with the CHARMM36 all-atom force field [37].
NRXN2 variant structure stability predictions
The mCSM webserver was used to assess the effect of the mutation on the stability of the pro-
tein structure of NRNX2 [44]. First, we extracted six structures (every 10ns) in total over the
last 50ns of the simulation trajectory. Next, each WT structure without NAG was uploaded to
the webserver and the position of the variant was specified as G889D on the webpage. mCSM
calculates a Delta-delta G stability score and provides a phenotypic assessment of the score
with destabilizing scores being negative, while stabilizing scores are positive [45].
Results
Description of the family
The complete pedigree of this family, which is denoted as family ZA253, contains 57 individu-
als, and in total, eight members were reported to have PD. A simplified version of the pedigree
indicating the family members, who took part in this study, is shown in Fig 1. The patient
labelled as individual III-8 (proband) was the first individual to be diagnosed with PD and his
age at onset (AAO) was 48 years. He initially presented with anxiety and difficulty with the use
of his leg following a general anesthetic. He later developed moderate to high amplitude rest
tremor. Levodopa improved his condition markedly, but he developed dystonia of the left leg
within weeks of starting medication. His siblings were subsequently assessed, and his brother
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(III-7) was also confirmed as having PD. His AAO was 42 years, at which time he developed dif-
ficulties with concentration together with weakness of the legs and gait disturbances. On exami-
nation, he had marked dystonia of the left arm, and very asymmetrical bradykinesia and rigidity.
Patient IV-2, the nephew of the two affected siblings, was diagnosed with early-onset PD at the
age of 37 years. Examination revealed facial dystonia, rigidity at the right wrist, mild generalized
bradykinesia, and slowness of gait [Unified Parkinson’s Disease Rating Scale (UPDRS) motor
score 16]. Furthermore, his mother (individual III-6) was examined at the age of 67 years; at that
time her examination was normal. Repeat examination three years later (aged 70 years) showed
mild generalized bradykinesia (UPDRS motor score 11), although she had no complaints. Indi-
vidual III-2 was the most recent individual in the family to be diagnosed with PD, in 2017. How-
ever, she presented as typical idiopathic PD, with AAO of 75 years. The symptoms at the time of
diagnosis were tremor and rapid eye movement sleep behavior disorder, with no evidence of
dystonia. A summary of the family’s clinical characteristics is provided in S1 Table.
Whole exome sequencing
WES was performed on three of the affected family members (III-7, III-8 and IV-2). These
three patients all appear to have young onset PD, with prominent dystonia, resembling similar
cases with PRKN and PINK1 mutations. Moreover, all three cases are characterized by a long
duration of illness, mild autonomic impairment, and delayed and mild impairment of cogni-
tion, with absence of REM sleep behavior disorder. DNA of individual III-2 was not available
at the time that the WES was performed.
The WES metrics (S2 Table), revealed good overall coverage of the target regions in all
three individuals. For the data analysis, we assumed that the three affected individuals have the
same genetic cause of disease and that the mode of inheritance is autosomal dominant. Impor-
tantly, none of the known PD mutations were found in any of the affected individuals which
suggests that there is likely a novel PD-causing mutation in this family.
Fig 1. Pedigree of the South African family ZA253. For readability and confidentiality, the pedigree is greatly
simplified. Circles denote females and squares depict males. The filled in symbols indicate affected individuals. The
diagonal line indicates that the person is deceased, and the arrow indicates the proband. The numbers below each
individual is the laboratory ID number and age at onset of disease. Branches without clinically confirmed PD or
without DNA samples were omitted, but all known living family members with PD diagnoses are included.
https://doi.org/10.1371/journal.pone.0249324.g001
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After exclusion of synonymous, common, non-co-segregating and homozygous variants, a
total of nine novel or rare non-synonymous heterozygous variants were shared between the
three affected individuals. These variants are in nine genes, ACTN3 (Actinin Alpha 3), CCNF
(Cyclin F), CDC27 (Cell Division Cycle 27), CFAP65 (Cilia and Flagella Associated Protein
65), RFT1 (Requiring Fifty-Three 1), NRXN2 (Neurexin 2), POU2F1 (POU Class 1 Homeo-
box 1), TEP1 (Telomerase Associated Protein 1) and TUBB6 (Tubulin Beta 6 Class V).
Sanger sequencing of variants and co-segregation in family
Sanger sequencing validation was performed to ensure that the variants are not NGS artefacts,
and five variants in CCNF, CFAP65, RFT1, NRXN2 and TEP1 were validated. Thereafter, we
performed genotyping of the family and these results are summarized in Table 1. The most
recently diagnosed patient III-2 had only one of the five validated variants, p.T1023A in
CFAP65. The unaffected family members shared only one variant, p.C363S in CCNF, with the
affected individuals, which indicates that it may be a polymorphism.
Analysis using functional prediction tools
Various functional prediction tools were used to identify and prioritize variants that are pre-
dicted to have a major impact on the protein. Notably, none of the codon changes occurred in
the interchangeable third base position (wobble base). The results are summarized in Table 2
with the functional scores and predictions from SIFT, PolyPhen-2, MutationTaster, GERP++,
Table 1. Rare and novel exonic missense variants shared between the three affected individuals after variant filtering.
CFAP65 RFT1 NRXN2 TEP1 CCNF
p.T1023A p.A463G p.G849D p.Y412C p.C363S
Affected individuals III-8 (proband) Present Present Present Present Present
III-7 Present Present Present Present Present
IV-2 Present Present Present Present Present
III-6 Present Present Present Present Present
III-2 Present Absent Absent Absent Absent
Unaffected individuals III-4 Absent Absent Absent Absent Present
IV-1 Absent Absent Absent Absent Present
III-1 Absent Absent Absent Absent Present
III-5 Absent Absent Absent Absent Absent
Present, variant present; Absent, variant absent
https://doi.org/10.1371/journal.pone.0249324.t001
Table 2. In-silico functional tool scores and predictions for the five variants validated with Sanger sequencing.
Gene cDNA
position


















RFT1 c.C1450G p.A463G GCT)GGT 0.49;
Tolerated
0.001; Benign 0; Neutral 2,53; Conserved 4,96; Benign 0.042 Neutral
NRXN2 c.G3008A p.G849D GGC)GAC 0; Deleterious 0.973; Probably
damaging




TEP1 c.A1276G p.Y412C TAC)TGC 0.51;
Tolerated
0; Benign 0; Neutral -8,29; Not
conserved
0,00; Benign 0.050 Neutral
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CADD and Condel. The TEP1 p.Y412C variant was predicted to be benign across all of the dif-
ferent prediction tools with a CADD score of zero and with a GERP++ score of—8,29. The
conservation score implies that in the region of the genome where this variant occurs, there
are more substitutions than the average neutral site and thus indicates that this region may not
be under evolutionary constraint. The p.A463G variant in RFT1 was also predicted to be
benign by all of the tools though its conservation score (of 2,53) implies that it occurs in a
region that is evolutionarily-conserved. The p.T1023A variant in CFAP65 and the p.C363S
variant in CCNF are predicted to be pathogenic by most of the tools, and both have positive
scores indicating that they are found in conserved regions of the genome. The only variant
that was predicted to be pathogenic across all of the functional prediction tools was p.G849D
in NRXN2, which had a CADD score of 29,50 and a conservation score of 4,93 showing that
the level of evolutionary constraint inferred to be acting on this position is relatively high.
Frequency of variants in control populations
To determine the frequency of the five variants in controls, a search was performed of publicly
available databases including the 1000 Genomes Project, dbSNP and gnomAD. This revealed
that four of the variants are either extremely rare or are novel according to data available on
African American, American, East Asian, South Asian, Finnish and Non-Finnish European
populations. CFAP65 p.T1023A was found in gnomAD with a MAF frequency of 8.88e-5 (25
out of 281690 alleles) (https://gnomad.broadinstitute.org/variant/2-219886565-T-C?dataset=
gnomad_r2_1).
When assessing the frequency of these variants, it is important to consider not just the pub-
licly available online databases but also to screen ethnically matched controls. Therefore, we
screened South African ethnic-matched controls, but none of the variants was present in these
individuals. The TEP1 p.Y412C, RFT1 p.A463G and CCNF p.C363S variants were screened in
192 individuals, and the CFAP65 p.T1023A and NRXN2 p.G849D variants were screened in
218 and 216 individuals, respectively.
Pathway and expression analysis
To add further information about the possible causal role of the variants, gene expression pro-
files were assessed using publicly available databases, namely the Allen Brain Atlas [46] and the
Human Protein Atlas [47]. Pathway analysis was also performed using KEGG Pathways Analy-
sis [48] and Panther Pathway Analysis [49] to determine if any of the five candidates are co-
expressed, co-regulated or co- localize with each other or any of the known PD genes. This
analysis also shows if the variants and any of the known PD genes are functionally related or
impact a pathway of interest or even a trait of interest such as neuronal development, regula-
tion and functioning. The results show that none of the five proteins are co-expressed, co-reg-
ulated or co-localize with each other or any of the proteins encoded by the known PD genes.
Notably, NRXN2 was found to be highly expressed in the brain including the substantia nigra
(https://www.proteinatlas.org/ENSG00000110076-NRXN2/tissue). This is the region of the
brain predominantly involved in PD pathogenesis and also thought to be involved in pathways
that regulate synaptic functioning, neurotransmitter secretion and neuronal cell-to-cell adhe-
sion. RFT1 is also expressed in the brain, however not particularly defined to any specific
region. RTF1 was implicated in pathways of protein metabolism and the endoplasmic reticu-
lum membrane network. CFAP65 was associated with the motile cilia pathway, TEP1 is
reported to be involved in apoptotic pathways and in assembling telomerase components in
cell signaling and CCNF was associated with pathways of ubiquitination and cell cycle
regulation.
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Selection of NRXN2
After the above analyses, we prioritized one candidate gene (NRXN2) for further study. As
mentioned previously, even though the CCNF p.C363S variant was predicted to be deleterious
by most of the prediction tools, it was excluded at this stage as it was found in unaffected family
members. The variants in TEP1 (p.Y412C) and RTF1 (p.A463G) were predicted to be benign
across all the prediction tools used, therefore they were also excluded. Although the p.T1023A
variant in CFAP65 was predicted to be deleterious by the majority of the prediction tools, it
functions specifically in ciliac processes, and thus is unlikely to be involved in PD pathobiol-
ogy. Importantly, while affected individual III-2 has the CFAP65 variant, we suspect that she is
a phenocopy. Evidence for this is that her phenotype is typical late-onset PD that is unlike the
other affected family members. Consequently, the p.G849D variant in NRXN2 is considered to
be the strongest candidate of the five variants. All of the computational algorithms predicted
the G849D substitution as being potentially deleterious. The position where this variant occurs
was reported to be highly conserved by GERP++ and it resulted in a codon change from a
small, non-polar amino acid to a larger, negatively charged, polar one. None of the controls
obtained from the online databases or in the local population had the variant. The NRXN2 var-
iant was also not present in exomes of 600 probands of French, North African and Turkish ori-
gins with predominantly early-onset PD (Suzanne Lesage, personal communication). NRXN2
was reported by two expression databases to be expressed in the brain and specifically in the
substantia nigra, a key brain region involved in PD pathogenesis. NRXN2 was therefore
selected for further studies involving protein structure modelling and simulation analysis.
NRXN2 protein model
The Swissmodel webserver [33] search, identified homologous template PDBID: 3R05 crystal
structure of neurexin 1 alpha [Laminin neurexin sex hormone binding globulin domains
(LNS1-LNS6), with splice insert SS3, Bos taurus (cow)] as a highly similar protein to human
NRNX2. The template 3R05 was chosen to construct a three-dimensional (3D) structure for
NRXN2 because it shared 71% sequence identity and over 50% structural similarity with our
target protein. The 3D structure built for human NRXN2 is structurally similar to template
3R05 displaying the five LNS2-6 and two EGF-like repeats excluding LNS domain 1 and one
EGF-like domain (Fig 2). The protein model predicted for human NRXN2 had a GMQE score
of 0.51 [value between 0 and 1] and a QMEAN Z-score of -1.67 that are close to zero and
higher than -4, suggesting high reliability in the quality of the predicted protein model. Super-
imposition of the predicted model onto the homologous template structure indicated a root
mean square deviation (RMSD) value of 0.226Å, which is less than 2Å, suggesting very little
deviation in the main chain backbone atoms of the protein model and the template. Further-
more, the Glycine residue (G849) in the template and homology model is conserved and has a
positive phi and psi dihedral angle conformation and therefore any amino acid substitution at
this position will have a significant effect on the protein structure.
NRXN2 molecular dynamic simulation analysis and stability predictions
Four simulation systems were prepared for NRXN2 analysis. These are wild type (WT)
NRXN2 with and without the sugar moiety, N-acetyl-D-glucosamine (NAG), and mutant
(MUT) NRXN2 with and without NAG. NAG was used in this analysis as it is important for
the glycosylation of NRXN2 and it was extracted from the homologous template. The kinetic
energy and thermodynamic properties were found to fluctuate around stable values with the
potential and total energies values fluctuating at negative 1X10-6 values and the temperature
fluctuating around 300K for the four NRXN2 systems (S1–S3 Figs).
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Measuring the mean and standard deviation of the RMSD values for the four systems indi-
cated lower values of 1.61 nm ± 0.26 for the WT system without NAG compared to the MUT
system without NAG of 2.16 nm ± 0.60 (Fig 3A). However, for the WT system with NAG, a
higher RMSD value (2.25 nm ± 0.52) was observed compared to the MUT system with NAG
(1.54 nm ± 0.55) (Fig 3A). The RMSD showed that the MUT systems with and without NAG
reached equilibrium after 50ns, therefore subsequent analysis considered only the last 50ns of
the simulation trajectories. The average root mean square fluctuation (RMSF) per-residue val-
ues for the four systems indicated lower fluctuation values for the WT system without NAG
(0.32 nm ± 0.14) compared to the MUT system without NAG (0.53 nm ± 0.24) (Fig 3B). Fur-
thermore, the RMSF fluctuation per-residue values for the other two systems with NAG indi-
cated slightly lower values of 0.37 nm ± 0.18 for the WT system compared to 0.40 nm ± 0.16
for the MUT system (Fig 3B). Similarly, the radius of gyration values and the solvent accessible
surface area values for the WT NRXN2 without NAG were significantly lower than that of the
other three systems. The calculated Rg values for the backbone atoms for WT NRXN2 without
NAG was lower (3.90 nm ± 0.03) compared to MUT NRXN2 without NAG, WT and MUT
NRXN2 with NAG, (5.01 nm ± 0.10; 4.76 nm ± 0.11; 5.13 nm ± 0.08, respectively) (Fig 3C).
The solvent accessible surface area values of the protein for WT and MUT NRXN2 in absence
of NAG were lower (480.84 nm ± 5.43; 490.59 nm ± 4.46) compared to the WT and MUT
NRXN2 in the presence of NAG (507.63 nm ± 4.26; 495.76 nm ± 4.78) (Fig 3D).
Calculation of the contribution of each of the top ten principal components (PCs) indicated
that the first two PCs contributed significantly to the movement of the protein. For each sys-
tem, PC1 contributed to 70%, 46%, 60% and 37% to WT no NAG, WT with NAG, MUT no
NAG, and MUT with NAG for NRXN2, respectively. While, PC2 contributed 8%, 19%, 15%
and 29% to WT no NAG, WT with NAG, MUT no NAG, and MUT with NAG for NRXN2,
respectively. Therefore, 2D projections of the first and second principal components for all
Fig 2. Swissmodel predicted 3-dimensional (3D) structure for human NRXN2 with mutation p.G849D (p.G889D) in complex with N-acetyl-D-glucosamine
(NAG). Each domain is colour coded, EGF-like domains are labelled B and C, substrate NAG are labelled as well as the mutation, p.G889D in our protein model.
https://doi.org/10.1371/journal.pone.0249324.g002
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four systems were plotted and shown in Fig 4. Calculation of the covariance matrix values after
diagonalization showed a significant decrease for the WT NRXN2 without NAG (237.82 nm)
system compared to the other three systems MUT without NAG, WT and MUT with NAG
(612.38 nm; 508.19 nm; 554.72 nm, respectively) (Fig 4).
We performed interaction analysis to determine which residues played a role in the binding
of NAG to the protein in the WT NRXN2 and identified one conserved hydrogen bond inter-
action with Arg1266 (in our model) as an important anchor point that could be exploited for
drug design (S4 Fig). The first repeat of the four simulation systems showed similar results to
the first run for thermodynamic and kinetic energy parameters (S5–S7 Figs). Additionally,
equilibrium is reached after 50ns of the simulation run and the WT system without NAG had
higher stability values based on RMSD analysis compared to the MUT system without NAG
(S8 Fig). Similarly, the repeat 2 showed convergence of energy and temperature terms (S9–S11
Fig 3. Trajectory analysis of wild type (WT) NRNX2 and mutant (MUT) NRNX2, both with and without NAG. (A) root mean square deviation (RMSD) deviation of
the backbone atoms. MEAN + STDEV (1.61mm ± 0.26, 2.26mm ± 0.52, 2.16mm ± 0.60 and 1.54mm ± 0.55). (B) The average RMSF fluctuation per-residue. MEAN +
STDEV (0.31mm ± 0.14, 0.54mm ± 0.24, 0.37mm ± 0.18 and 0.40mm ± 0.19). (C) Radius of gyration of the backbone atoms. MEAN + STDEV (3.90mm ± 0.03,
5.01mm ± 0.10, 4.67mm ± 0.11 and 5.13mm ± 0.08). (D) Solvent accessible surface area of the protein. MEAN + STDEV (3.90mm ± 0.03, 5.01mm ± 0.10, 4.67mm ± 0.11
and 5.13mm ± 0.08). Line colors: WT_noNAG = green, MUT_noNAG = light magenta, WT_NAG = red and MUT_NAG = blue.
https://doi.org/10.1371/journal.pone.0249324.g003
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Figs), this is in agreement with repeat 1, while the RMSD analysis for repeat 2 confirmed stabil-
ity values of repeat 1 (S12 Fig).
The change in secondary structure for the NRNX2 WT and MUT without NAG is visually
shown in a short simulation movie over the last 50ns for the simulation trajectory (S1 and S2
File). In these movies, the LNS6 domain undergoes large transitions between flexed and
extended conformations for the mutant structure without NAG while the LNS6 domain for
the WT without NAG remains in a stable flexed conformation. FES analysis of the four systems
identified several (up to 6) metastable conformations for the WT system without NAG, while
the MUT without NAG showed only one energy minima state. In contrast, the other two sys-
tems with NAG adopted at least one metastable state for the MUT structure and none for the
WT structure (Fig 5A–5D). The WT system without NAG seems to be more stable than the
MUT without NAG due to the six energy minima states. The opposite is found for the systems
with NAG, as the MUT with NAG becomes more stable while the WT with NAG becomes
more flexible. Furthermore, stability predictions using the mCSM webserver was performed to
determine the effect of the novel variant p.G849D (in our model p.G889D) on the NRXN2
Fig 4. Two-dimensional (2D) projections of the first and second principal components for the WT NRNX2, MUT NRNX2 without NAG and WT NRNX2, MUT
NRNX2 with NAG systems. Covariance matrix after diagonalization values for each system; 237.82 nm, 612.38 nm, 508.19 nm and 554.72 nm. Line colors:
WT_noNAG = green, MUT_noNAG = light magenta, WT_NAG = red and MUT_NAG = blue.
https://doi.org/10.1371/journal.pone.0249324.g004
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protein structure. The results were in concordance for all six structures extracted over the last
50 ns indicating destabilizing delta-delta (ΔΔG) scores of -1.389, -1.131, -1.573, -1.183, -1.298
and -1.596 for 50, 60, 70, 80, 90 and 100 ns frames, respectively.
Discussion
The absence of known PD mutations in this South African family led to the conclusion that a
novel mutation could be responsible for the disease phenotype. Four variants in CFAP65,
RFT1, NRXN2 and TEP1 are shared by four of the affected family members and are not in the
unaffected family members or the controls. It is possible that the variants in any of these genes
or even in another gene is responsible for the disease in this family, however, at this stage, the
NRXN2 p.G849D variant was selected for further study. It is the top candidate even though
patient III-2 does not share this variant, as this patient may be a phenocopy, known to occur in
PD families [26, 50], since she has typical, late-onset sporadic PD unlike the other four affected
individuals. This highlights the complexity of interpreting familial co-segregation in disorders
where the genetic disease can be indistinguishable from idiopathic forms.
The NRXN2 p.G849D change is from glycine a small, non-polar, side chain free amino
acid, to aspartic acid a larger, negatively charged amino acid with a carboxyl group side chain.
The 3D structure predicted for NRXN2 provided deeper insight into the structural implica-
tions of G849D on NRXN2 protein structure. The overall structure of NRXN2 is similar to
that of the homologous template 3r05, and adopts a similar fold. Using molecular dynamic
simulations to understand the overall movement of the protein structure added support to the
destabilizing effect of the variant p.G849D on the mobility of the LNS6 domain (residues
1137–1343 in our model). Trajectory analysis confirmed the destabilizing effect of the variant
Fig 5. Two-dimensional (2D) free energy landscapes plotted for NRXN2 along two order parameters root mean
square deviation (RMSD) to average structure and Rg. (A) WT without NAG (B) MUT without NAG (C) WT with
NAG (D) MUT with NAG. Blue regions represent low energy conformational states while red indicate high energy
states.
https://doi.org/10.1371/journal.pone.0249324.g005
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on the protein structure and the predicted increase in the flexibility of the LNS6 domain might
prevent the binding of neuroligins and synaptic organization. Additionally, we showed that
adding NAG to the mutant ‘system’ restored some stability to the NRXN2 protein. From these
findings, we hypothesize that the novel variant p.G849D (in our model p.G889D) is destabiliz-
ing to NRXN2’s protein structure, and that adding NAG to the mutated structure might
reduce flexibility and restore its ability to interact with its known interactors such as
neuroligin.
NRXN2 has been linked to pathways associated with neuronal and synaptic functioning,
and expression analysis showed that it is expressed in the pars reticulata of the substantia
nigra, the main region of the brain affected in PD. Its predicted functions range from neuronal
cell-cell adhesion, neurotransmitter secretion regulation to synaptic regulation. Indeed,
NRXN2 is known to mediate synaptic organization and differentiation [51, 52]. Recently,
Naito et al. [51] investigated whether neurexins plays a role in Alzheimer’s disease (AD), and
observed an interaction between amyloid beta (Aβ) oligomers and NRXN1/2 that diminished
presynaptic organization [51]. Additionally, Aβ oligomers were found to interact specifically
with NRXN2α and neuroligin 1 to mediate synapse damage and memory loss in mice [53].
Limitations of this study are the limited sequencing scope of WES, which includes its inabil-
ity to accurately detect copy number [54, 55] and non-coding variants [56], and the fact that
each of the functional prediction tools used relies on their own in-built algorithm, which can
produce inaccurate results. Another limitation is that the LNS-1 domain of the protein could
not be modelled due to the lack of sequence coverage between the target sequence and homol-
ogous template structure. Also, the short simulations times (100ns) used may not allow
NRXN2 to sample enough of the protein’s energy minima landscape or phase space thereby
missing important energetic conformations.
In conclusion, we identified a novel candidate gene, NRXN2, for PD thereby potentially
implicating synaptic dysfunction in neuronal cell death. Future studies will involve wet-labora-
tory functional studies in relevant disease models to determine the biological significance of
the variant identified.
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